Role of transglutaminases in cuff-induced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 77-84

  Matlung, Hanke L ^a   VanBavel, Ed ^a   van den Akker, Jeroen ^a   de Vries, Carlie J M ^a   Bakker, Erik N T P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Factor XIII; Macrophages; Transglutaminases

Indexed keywords

1,3,4,5 TETRAMETHYL 2 [(2 OXOPROPYL)THIO]IMIDAZOLIUM CHLORIDE; APOLIPOPROTEIN E3; BLOOD CLOTTING FACTOR 13A; CHOLESTEROL; COMPLEMENTARY DNA; ENZYME INHIBITOR; L 682777; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BODY WEIGHT; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; FEMORAL ARTERY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; CELL ADHESION; FACTOR XIII; FEMORAL ARTERY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HL-60 CELLS; HUMANS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGLUTAMINASES;

EID: 77958486202     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.054     Document Type: Article

References (31)

1. AbdAlla S., Lother H., Langer A., el Faramawy Y., Quitterer U. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 2004, 119:343-354.
2. Boisvert W.A., Rose D.M., Boullier A., et al. Leukocyte transglutaminase 2 expression limits atherosclerotic lesion size. Arterioscler Thromb Vasc Biol 2006, 26:563-569.
3. Van Herck J.L., Schrijvers D.M., De Meyer G.R., et al. Transglutaminase 2 deficiency decreases plaque fibrosis and increases plaque inflammation in apolipoprotein-E-deficient mice. J Vasc Res 2009, 47:231-240.
4. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003, 4:140-156.
5. Bakker E.N., Pistea A., VanBavel E. Transglutaminases in vascular biology: relevance for vascular remodeling and atherosclerosis. J Vasc Res 2008, 45:271-278.
6. Baumgartner W., Weth A. Transglutaminase 1 stabilizes beta-actin in endothelial cells correlating with a stabilization of intercellular junctions. J Vasc Res 2007, 44:234-240.
7. Ohura N., Yamamoto K., Ichioka S., et al. Global analysis of shear stress-responsive genes in vascular endothelial cells. J Atheroscler Thromb 2003, 10:304-313.
8. Auld G.C., Ritchie H., Robbie L.A., Booth N.A. Thrombin upregulates tissue transglutaminase in endothelial cells: a potential role for tissue transglutaminase in stability of atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2001, 21:1689-1694.
9. Akimov S.S., Belkin A.M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 2001, 98:1567-1576.
10. Dardik R., Krapp T., Rosenthal E., Loscalzo J., Inbal A. Effect of FXIII on monocyte and fibroblast function. Cell Physiol Biochem 2007, 19:113-120.
11. Jayo A., Conde I., Lastres P., Jimenez-Yuste V., Gonzalez-Manchon C. Possible role for cellular FXIII in monocyte-derived dendritic cell motility. Eur J Cell Biol 2009, 88:423-431.
12. Matlung H.L., Groen H.C., de Vos J., et al. Calcification locates to transglutaminases in advanced human atherosclerotic lesions. Am J Pathol 2009, 175:1374-1379.
13. Bakker E.N., Buus C.L., Spaan J.A., et al. Small artery remodeling depends on tissue-type transglutaminase. Circ Res 2005, 96:119-126.
14. Bakker E.N., Pistea A., Spaan J.A., et al. Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase: possible compensation by macrophage-derived factor XIII. Circ Res 2006, 99:86-92.
15. Pistea A., Bakker E.N., Spaan J.A., Hardeman M.R., van Rooijen N., VanBavel E. Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases. J Vasc Res 2008, 45:10-18.
16. Tarantino U., Oliva F., Taurisano G., et al. FXIIIA and TGF-beta over-expression produces normal musculo-skeletal phenotype in TG2-/- mice. Amino Acids 2009, 36:679-684.
17. van den Maagdenberg A.M., Hofker M.H., Krimpenfort P.J., et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993, 268:10540-10545.
18. Lardenoye J.H., Delsing D.J., de Vries M.R., et al. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. Circ Res 2000, 87:248-253.
19. Freund K.F., Doshi K.P., Gaul S.L., et al. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994, 33:10109-10119.
20. el Alaoui S., Legastelois S., Roch A.M., Chantepie J., Quash G. Transglutaminase activity and N epsilon (gamma glutamyl) lysine isopeptide levels during cell growth: an enzymic and immunological study. Int J Cancer 1991, 48:221-226.
21. Barsigian C., Stern A.M., Martinez J. Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators. J Biol Chem 1991, 266:22501-22509.
22. Haroon Z.A., Wannenburg T., Gupta M., Greenberg C.S., Wallin R., Sane D.C. Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest 2001, 81:83-93.
23. Sumi Y., Inoue N., Azumi H., et al. Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability. Atherosclerosis 2002, 160:31-39.
24. Williams H., Pease R.J., Newell L.M., et al. Effect of transglutaminase 2 (TG2) deficiency on atherosclerotic plaque stability in the apolipoprotein E deficient mouse. Atherosclerosis 2010, 210:94-99.
25. Kawai J., Ando K., Tojo A., et al. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 2004, 109:1147-1153.
26. Ozumi K., Tasaki H., Takatsu H., et al. Extracellular superoxide dismutase overexpression reduces cuff-induced arterial neointimal formation. Atherosclerosis 2005, 181:55-62.
27. Iismaa S.E., Mearns B.M., Lorand L., Graham R.M. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 2009, 89:991-1023.
28. Nahrendorf M., Aikawa E., Figueiredo J.L., et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008, 29:445-454.
29. Iyer S., Ferreri D.M., DeCocco N.C., Minnear F.L., Vincent P.A. VE-cadherin-p120 interaction is required for maintenance of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1143-L1153.
30. Kojima S., Nara K., Rifkin D.B. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993, 121:439-448.
31. Jensen P.H., Lorand L., Ebbesen P., Gliemann J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur J Biochem 1993, 214:141-146.